Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

Simulations Plus has recently declined after its Q3 2025 report, despite having a healthy revenue growth and adjusted EPS beat. This decline was mostly driven by a non‑cash impairment and lowered ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its ...

The key market opportunities in the Global In Silico Clinical Trials Market include the potential to significantly cut R&D costs through computer modeling and simulation, thus reducing reliance on ...